C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform
-Multiple oncology-focused programs poised to enter clinical trials in 2021 and 2022- WATERTOWN, Mass.–(BUSINESS WIRE)–C4 Therapeutics, Inc. (C4T), a biotechnology…